ADRIAN THOMAS: Open Payments
NPI 1407638836 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$944 in 42 payments from 11 companies in 2025. Trend: 2023 $22 · 2024 $474 · 2025 $944
Food & beverage: $944
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $229 |
| ABBVIE INC. | 15 | $146 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $137 |
| Teva Pharmaceuticals USA, Inc. | 1 | $105 |
| Alkermes, Inc. | 4 | $92 |
| Neurocrine BioSciences, Inc. | 3 | $77 |
| Janssen Pharmaceuticals, Inc | 3 | $60 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $22 |
Products named: REXULTI, VRAYLAR, CAPLYTA, AUSTEDO XR, ARISTADA, INGREZZA, SPRAVATO, Auvelity.
Industry payments across AL — which companies pay providers there.
